Soluble polypeptides for use in treating autoimmune and inflammatory disorders

Details for Australian Patent Application No. 2009327058 (hide)

Owner Novartis AG

Inventors Raymond, Marianne; Sarfati, Marie; Welzenbach, Karl; Woisetschlaeger, Maximilian

Agent Davies Collison Cave

Pub. Number AU-A-2009327058

PCT Pub. Number WO2010/070047

Priority 08172751.3 23.12.08 EP; 61/203,558 22.12.08 US; 08172369.4 19.12.08 EP

Filing date 17 December 2009

Wipo publication date 24 June 2010

International Classifications

C07K 14/435 (2006.01) Peptides having more than 20 amino acids - from animals

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

C12N 1/15 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/68 (2006.01) Mutation or genetic engineering

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/070047 Priority application(s): WO2010/070047

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009327061-A dose setting element for a drug delivery device and drug delivery device with a dose setting element

2009327055-Compressed air tank for utility vehicles and method of manufacture